Catherine Pickering is leading iOnctura, which is focused on solving the problem of cancer resistance both at the tumor and around its environment

Co-Founders Sheila Gujrathi and Julia Owens talk about the creation of the Biotech CEO Sisterhood and the new dimensions and next steps it is taking as an organization ahead

They describe the Sisterhood's modest beginnings, its impact already, and plans for the future. It now has a 501c3 charity structure and more formal leadership, and there are new efforts to reach other c-suite level women in biotech.

Biotech leader Sheila Gujrathi discusses her new book, The Mirror Effect, which she wrote for her younger self, today's peers, and the next generation of female leaders in business

Interviewed by Sisterhood editorial board member Grace Colón, Dr. Gujrathi discusses a three pillar framework for success she has learned during her career in life sciences: know thyself, understand your environment, and set yourself up for success.

Stealth BioTherapeutics' CEO Reenie McCarthy describes the fortitude and close relationship with a patient community that led to the first approved therapy for Barth Syndrome

Interviewed by Sisterhood editorial board member Erika Smith, Reenie McCarthy discusses how working with the Barth Syndrome Community, an ultra rare disease, helped the company better understand outcomes that are important to daily life for these patients. She also highlights the role that mitochondria play in biology, and the future of treatments for diseases of mitochondrial dysfunction.

Hanadie Yousef leads Juvena Therapeutics, a company developing protein based therapeutics that are tissue restorative for muscle and metabolic diseases

She describes the process of how the company's computing platform sorts through proteins that are secreted by stem cells and screens them for therapeutic potential. Plus, the lead clinical program for muscle conditions and also a partnership with Lilly in the obesity space.

Catherine Pickering is leading iOnctura, which is focused on solving the problem of cancer resistance both at the tumor and around its environment

She discusses the approach and the company's lead program, which targets PI3Kδ. Plus, and autotaxin program for cancer and TGF-β.